Leading brokerage Axis Direct has identified Multi Commodity Exchange of India (MCX), Thyrocare Technologies, and Innova Captab as top stocks for traders, recommending 'Buy' ratings for all three. Rajesh Palviya, Head of Research at Axis Direct, provided key technical levels, target prices, and stop-loss recommendations, noting strong uptrends and bullish sentiments across these scrips.
Innova Captab: Strong Uptrend Confirmed
Innova Captab is currently exhibiting a robust uptrend on both daily and weekly charts, characterized by a consistent formation of higher tops and bottoms. The stock is trading comfortably above its 20, 50, 100, and 200-day Simple Moving Averages (SMAs), which are also rising in conjunction with the price, further reinforcing the bullish trend. Technical indicators, including a daily 'Bollinger Band' buy signal and favorable daily, weekly, and monthly Relative Strength Index (RSI), suggest increasing momentum and strength across all timeframes. Axis Direct recommends buying and accumulating Innova Captab, setting a target price range of Rs 1,080-1,120 with a stop loss at Rs 995. The downside support zone is identified between Rs 1,010 and Rs 980.
Multi Commodity Exchange of India (MCX): Trendline Breakout
MCX has demonstrated a significant technical move, decisively breaking past its month-long down-sloping trendline at Rs 2,760 on a closing basis, supported by substantial trading volumes. The stock has successfully reclaimed and sustained above its 20, 50, and 100-day SMAs, signaling a shift towards bullish sentiment. Both daily and weekly RSI are positioned favorably, indicating a rising strength across different time horizons. Investors are advised to consider buying, holding, and accumulating MCX. The expected upside target for MCX is between Rs 3,000 and Rs 3,150, with a recommended stop loss at Rs 2,770. The stock's downside support zone lies between Rs 2,800 and Rs 2,740.
Thyrocare Technologies: Consistent Bullish Momentum
Thyrocare Technologies is in a clear and strong uptrend across all timeframes, consistently forming higher tops and bottoms, which is a classic indicator of bullish sentiment. The stock is well-positioned above its 20, 50, 100, and 200-day SMAs, with these averages also trending upwards alongside the price, reaffirming the bullish outlook. The daily, weekly, and monthly RSI are all in favorable territories, signaling robust strength. Additionally, both daily and weekly 'Bollinger Band' buy signals point to increasing momentum. Axis Direct suggests buying, holding, and accumulating Thyrocare. The target price range for Thyrocare is set at Rs 680-750, with a stop loss at Rs 615. The downside support zone for the stock is between Rs 624 and Rs 606.
Disclaimer: This article provides stock market information for informational purposes only and should not be construed as investment advice. Readers are encouraged to consult with a qualified financial advisor before making any investment decisions.